Emeis Stock Climbs 3.46% to €15.25, Challenging Resistance at €15.29
Mid-afternoon Thursday, Emeis stock has risen by 3.46% to €15.25 in a SBF 120 that is up by 0.84%. The stock is among the top performers in the index and is nearing its resistance level at €15.29. The annual gain now stands at 30.74%.
Emeis Ranks Among the Leaders of the SBF 120, Testing Resistance at €15.29
Emeis is trading at €15.25 mid-afternoon, just cents away from its identified technical resistance at €15.29. Breaking through this threshold could pave the way to levels not seen for several months. The session is occurring in a positively oriented SBF 120 (+0.84%), with the CAC 40 up by 0.83% at 8,074.73 points. The stock ranks among the strongest rises in the SBF 120, trailing behind Derichebourg, Ubisoft, SES, and Elior. Today's rise brings the annual gain to 30.74%, while the weekly performance remains limited to -0.26%. Over three months, the gain reaches 3.88%.
A Tense Technical Setup Brings the Price Close to the Upper Bollinger Bands
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The price is now above its three moving averages: MM20 at €14.41 (+5.83%), MM50 at €14.02, and MM200 at €13.74. This configuration confirms the medium-term bullish momentum that started at the beginning of the year. The RSI at 54 remains in a neutral zone, leaving room before a signal of overheating. However, the price is at the upper end of the Bollinger Bands, 92% of the range, close to the upper limit at €15.42. This proximity signals a potential short-term overbought zone. It is worth recalling that the organic growth of 6.3% in the first quarter, published on May 7, and the confirmation of the EBITDAR 2026 guidance (growth exceeding 10%) have shaped the recent trajectory. Sustained crossing of the €15.29 mark is the next technical milestone to watch.
SectorServices et infrastructure de santé›Etablissements de santé / EHPAD
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 4 543 millions d'euros
Quarterly revenue: 4 543 millions d'euros
Revenue growth: 3,5 %
Guidance from the release
« Les tendances observées lors des 9 premiers mois de l'année 2026 confortent emeis dans l'atteinte des objectifs pour 2026, objectifs par ailleurs relevés fin juillet. »
Risks mentioned
Health crises linked to flu outbreaks and heat waves requiring proactive management
Macroeconomic uncertainty and risk of return to inflation impacting operating expenses
Dependency on continued execution of operational efficiency programs such as the Boost initiative in France
Opportunities identified
Strong like-for-like revenue growth of +6.0% driven by improved occupancy rates and favorable pricing effects
Average occupancy rate now above 90% with +2.9 pts annual increase, particularly strong in nursing homes (+3.1 pts)
Structural demographic tailwind with European senior population aged 85+ expected to grow over 30% in next 10 years
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
